Literature DB >> 2577153

Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance.

J A Posada1, E M McKeegan, K F Worthington, M J Morin, S Jaken, T R Tritton.   

Abstract

Among the many phenotypic characteristics of multidrug resistance (MDR), the presence of P-glycoprotein is nearly always observed, and it appears that the plasma membrane of the multidrug resistant cell is integrally involved in controlling drug resistance. Another membrane-associated protein kinase, protein kinase C (PKC), has been shown to regulate the flow of information to the cell interior and to control the efflux of a number of different compounds. We therefore initiated a study of PKC and MDR. We found that multidrug resistant sublines from both mouse sarcoma 180 and human KB lines exhibited 80-90% increases in basal PKC activity. The mechanism of the increase appears to be quite different in the two cell lines. The human KB cells overexpress the alpha isozyme of PKC, commensurate with the increase in alpha-PKC protein, whereas the mouse cells do not overexpress alpha-mRNA but increase alpha-PKC protein. Furthermore, it appears that PKC activity plays a functional role in drug resistance, since inhibition of endogenous PKC activity by staurosporine resulted in decreased resistance to Adriamycin. We also found that phosphorylation of MDR cell membrane vesicles by purified PKC, followed by immunoprecipitation of P-glycoprotein with monoclonal antibody C219, resulted in a level of phosphorylation of P-glycoprotein that was greater than the endogenous phosphorylation level. The data presented indicate that MDR cells of diverse species exhibited enhanced PKC activity but that the mechanisms were different. The increased kinase activity may have biological relevance to MDR since PKC appears to be coupled to P-glycoprotein function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577153     DOI: 10.3727/095535489820874922

Source DB:  PubMed          Journal:  Cancer Commun        ISSN: 0955-3541


  16 in total

1.  Protein kinases and multidrug resistance.

Authors:  M G Rumsby; L Drew; J R Warr
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation.

Authors:  V M Richon; N Weich; L Leng; H Kiyokawa; L Ngo; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

Review 3.  Effects of phosphorylation of P-glycoprotein on multidrug resistance.

Authors:  U A Germann; T C Chambers; S V Ambudkar; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

Review 4.  Molecular analysis of the multidrug transporter.

Authors:  U A Germann
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Increased expression and DNA-binding activity of transcription factor Sp1 in doxorubicin-resistant HL-60 leukemia cells.

Authors:  F Borellini; A Aquino; S F Josephs; R I Glazer
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

6.  Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism.

Authors:  P J Bergman; K R Gravitt; N E Ward; P Beltran; K P Gupta; C A O'Brian
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

7.  Evaluation of 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)- hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro.

Authors:  E C Sha; M C Sha; S H Kaufmann
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 8.  Regulation of protein kinase C and role in cancer biology.

Authors:  G C Blobe; L M Obeid; Y A Hannun
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 9.  Studies on low-level MDR cells.

Authors:  G Belvedere; E Dolfini
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 10.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.